




INVESTOR PRESENTATION NOVEMBER 2026

Paul R. Gudonis, Chairman and CEO
David Henry, Chief Financial Officer

Conquering Upper Limb Paralysis with Wearable Medical Robotics

Legal Disclaimer

This presentation contains forward-looking statements regarding the trading of the Company's common stock on the NYSE American, the Company's plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Company's financial position and projections of future operating results, and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the Company's management and its knowledge of the relevant market. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. Forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties and other factors. These risks and uncertainties include, among others, risks related to the Company's liquidity and financial position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Investment Highlights

Created New Product Category for a Large, Unmet Need

First-Mover Advantage with Strong Competitive Position

Medicare Reimbursement and New Payer Contracts Expanding Patient Access


Growing Revenues from Recurring Patient Sources

Attractive Margin Profile with Opportunity for Scale Economics

Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease

Major Dx

- Stroke/CVA
- Traumatic Brain Injury
- Spinal Cord Injury
- Brachial Plexus Injury



Other Dx

- Cerebral Palsy
- Multiple Sclerosis
- ALS
- Spinal Muscular Atrophy
- Acute Flaccid Myelitis

Patient Journey: From Stroke to Rehab Therapy




ONSET	ACUTE CARE	SUB-ACUTE CARE	OUTPATIENT THERAPY (Incidence)	CHRONIC HEMIPARESIS (Prevalence)
Incidence: 800,000 Cases/Yr. in US	Onset → 1 week	1 week → 6 months	6–12 months	> 6–12 months


Patients are told "Get used to it – You'll never use your arm and hand again for the rest of your life"

Multi-Billion Dollar Market Opportunity @ $55K ASP

40,000 to 80,000 patients replenish the prevalence population each year



Annual Incidences



Prevalence Population


Senior Insured Population

Source: Kaiser Family Foundation

Source: Centers for Disease Control and Prevention, Christopher and Dana Reeve Foundation, Frontiers in Neurology, American Heart Association (*Stroke*) and Myomo base model estimates

Company Goal: Market Penetration

Expand MyoPro adoption to address a large unmet need: US market



400,000 – 800,000

Potential MyoPro candidates with Chronic Arm Paralysis in Prevalence Population

ANNUAL INCIDENCE

40,000 - 80,000

New cases per year after post-stroke therapy

> 4,000


MyoPros provided to patients since inception

Our Solution: The MyoPro Arm Brace -- Enabling Activities of Daily Living



How it Works: Myomo's Proprietary Technology


- **Brain-computer interface**
- **Interpret and amplify a patient's weak EMG signal**
- **35 Patents in U.S. and International markets valid through 2042.**



Massachusetts Institute of Technology

HARVARD MEDICAL SCHOOL

Myomo Mobility Platform: Technology and Commercial Infrastructure




Go to Market Approach Via 3 Distribution Channels

myomo my own motion

Direct-to-Patient Advertising (Social Media/TV)



Referrals from Rehab Hospitals (MyoConnect)




Orthotics & Prosthetics Clinics



---------- Recurring Patient Sources ----------

Now Over 500 MyoConnect Referring Facilities



Therapist Referrals Physician Referrals

Over 500 rehab hospitals and stroke clinics referring patients for a MyoPro

Growing number of facilities referring multiple patients

Expanding Myomo's commercial operations field staff

Insurance Reimbursement Supported by Clinical Research

Medicare

UnitedHealthcare Medicare Solutions

BlueCross BlueShield


Spitzenverband German Statutory Health Insurance

VA | U.S. Department of Veterans Affairs

Medicare Fee $68,800*



Subjects from our Patient Registry



Systematic review published in 2025


THE UNIVERSITY of UTAH

Randomized Controlled Trial underway


* Fee for MyoPro 2x Motion G

2026 Strategy Direction & Four Success Pillars


1. Shift to Recurring Patient Sources



2. Increase market access with additional payer contracts




3. Demonstrate operating leverage




Q3 2026:
Revenue ↑ 22%
Opex ↑ 6%
GM ↑ 750 bps

4. Invest in product development and research



Track Record: 10 Years of Revenue Growth



P&L and Key Balance Sheet Metrics

P&L

($000's)	Actual Q3'26	Actual Q3'25	YTD 2026	YTD 2025
Revenue	12,330	10,091	34,148	29,575
COGS	3,540	3,648	10,014	10,471
Gross Profit	8,790	6,443	24,134	19,104
Gross Margin	71.3%	63.8%	70.7%	64.6%
Operating Expenses:				
R&D	1,810	1,528	5,153	5,319
Selling, Clinincal & Mtkg	5,119	5,254	15,200	14,884
G&A	3,585	3,178	10,916	10,529
Total	10,514	9,960	31,269	30,732
Operating Loss	(1,724)	(3,517)	$ (7,135)	$(11,628)
Interest expense (income)	560	10	1,600	(289)
Other (income) expense	1,845	-	2,206	-
Income Taxes	104	136	322	421
	2,509	146	4,128	132
Net Loss	$ (4,233)	$ (3,663)	$(11,263)	$(11,760)

Key Balance Sheet Metrics


($000's)	Actual Q3'26		Actual Q2'26
Cash & Investments	$ 11,946		$ 13,452
Working Capital	11,229		13,916
Debt	12,649	*	12,609
Shareholders' Equity	2,751		5,829
Shares Outstanding	43,811	**	43,298

** Face value + accretion of final payment liability*


*** Includes unexercised pre-funded warrants*

Notes:
- Interest only on debt until May 2027
- Operating leverage in Q3 and YTD as guided
- Expect <$2M cash burn in total for 2H 2026

Where We're Headed: Longer-Term Vision



- > $100M in annual revenues
- 70% gross margin, positive EBITDA and cash flow.
- Durable business with recurring patient sources.
- Increased market access with improved reimbursement.
- Growth opportunities: New products, new indications, new markets.



Leadership Team & Board of Directors

Management Team Members



Paul R. Gudonis
Chairman & CEO
Scaled multiple tech co's, largest from $5M to $1.2B revenue (BBN/Genuity)



David Henry, CFO
Raised nearly $900M in capital for public companies



Katie McClure
Chief Commercial Officer
Demonstrated ability to accelerate revenues and scale medical device companies



Dr. Harry Kovelman
Chief Medical Officer
Track record of expanding patent access for new technologies



Galina Shtivelman
VP Human Resources
Leads efforts to scale human capital, talent acquisition and culture.



John Frijters
Managing Director - International
Experienced executive O&P Europe – based



Kathy Sawyers, PT, ATP Sr. Dir. – Clinical Outcomes
Oversees clinician training and user support



Colin Anderson
Sr. Dir – Global Operations
Experienced at scaling operations in med device industry



Dennis Shay Dir - QA/RA
Leads Quality and Regulatory Affairs efforts to enable global market access

Board of Directors



Thomas Kirk
Lead Independent Director
Former CEO, Hanger Clinics



Thomas Crowley
Board Member
Former Med Device CEO



Milton Morris
Board Member
Former President & CEO, Neuspera Medical; Boston Scientific exec



Heather Getz
Board Member
CEO and Director
TELA Bio



William Febbo
Board Member
CEO and Director
Performance Health Systems



Joseph Manko
Board Member
Senior Principal
Horton Capital Management

Thank You!



For Additional Information:

Paul R. Gudonis, CEO

paul@myomo.com

617-401-2623

David Henry, CFO

david.henry@myomo.com

508-344-5235